Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Burlington Free Press on MSN
UVM joins major study on drug use and treatment barriers across New England
The initiative, funded by a $12 million grant from the National Institute on Drug Abuse, will evaluate how people with ...
Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...
AllAfrica on MSN
Uganda Winning HIV Fight but Faces New Threats Among Youth - Uganda Aids Commission Warns
Uganda has recorded major gains against HIV, with significant declines in prevalence, new infections, and AIDS-related deaths, but emerging concerns among young people and persistent mother-to-child ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback